Latest News and Press Releases

DURHAM, N.C., March 14, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan,...

DURHAM, N.C., March 14, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it has entered into definitive agreements for the issuance and sale in a...

– Novan is a fully integrated pharmaceutical company with proven capabilities across drug development through to commercialization – – EPI Health adopts Novan corporate branding, creating unified...

– FDA completes filing review of application with no filing issues identified – – New Chemical Entity (“NCE”) has potential to be the first FDA-approved prescription product for molluscum in the...

DURHAM, N.C., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will...

– Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by the FDA and under standard review timelines – – Molluscum contagiosum is a viral skin infection that...

DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that EPI Health, LLC, a fully consolidated subsidiary of Novan, has entered...

– Agreement provides immediate access to cash flow – – EPI Health leveraging accounts receivables from commercial product sales to bolster working capital needs – DURHAM, N.C., Dec. 02, 2022 ...

– Paula Brown Stafford, President and Chief Executive Officer of Novan to participate in a live moderated panel discussion on Thursday, December 8th at 11:00 AM ET – DURHAM, N.C., Dec. 01, 2022 ...

– Rhofade prescriptions increased 37% for third quarter year-to-date from prior year – – Continued progress toward submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeted...